Please login to the form below
Hodgkin's lymphoma
This page shows the latest Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.
Chi-Med goes for third IPO in Hong Kong
1 inhibitor tislelizumab for relapsed/refractory classical Hodgkin’s lymphoma. ... The current pace of development of the biotech ecosystem in China is remarkable,” said Simon To, Chi-Med’s chairman.
Latest news
-
Precision BioSciences to raise $100m for off the shelf CAR-Ts
leukaemia and non-Hodgkin lymphoma (NHL). ... It’s a bold claim, but if the drug operates as claimed, then the company could offset some of the issues associated with first generation CAR-T therapies.
-
FDA begins speedy review of Celgene’s Revlimid combo in lymphoma
Known as R. 2. , the combination is being evaluated for those with previously treated follicular and marginal zone lymphoma, and if approved, the therapy could free patients of chemotherapy. ... of non-Hodgkin’s lymphoma), but failed to show any
-
Innovent gears up for PD-1 inhibitor launch in China
Tyvyt (sintilimab) was jointly developed by Innovent and partner Eli Lilly in China and was approved by the National Medical Products Administration (NMPA) for relapsed or refractory classical Hodgkin's lymphoma ... The home-grown PD-1 inhibitors join
-
Xencor’s Novartis-partnered bispecific on hold after patient deaths
It’s not the first CD3-targeting bispecific to run into safety concerns. ... In this case however the concerns were about liver toxicity. A few weeks earlier a trial of Affimed’s CD3- and CD19-targeting bispecific AFM11 in non-Hodgkin’s lymphoma
-
CMS proposes coverage scheme for CAR-T therapies
Sciences’ Yescarta (axicabtagene ciloleucel) given the nod shortly afterwards for various forms of non-Hodgkin’s lymphoma (NHL) including DLBCL. ... These one-time treatments have shown remarkable results in lymphoma and leukaemia patients who have
More from news
Approximately 19 fully matching, plus 133 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
One of the best known pharma leaders in China, Dr Wu’s most recent achievement was to build Pfizer into one of the top multinational firms in China. ... CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s
-
Pharma deals during October 2014
Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.
-
Interview: Kay Drake and Naoki Okamura, Astellas
The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,
-
Interview: Trevor Smith, Takeda
The significance of this lays in the evolving nature of Takeda's portfolio. ... Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Charles Morris appointed chief development officer at ImmunoGen
Previously worked in oncology for Allos, Cephalon and AstraZeneca. Immunogen has appointed Dr Charles Morris as the company's chief development officer. ... cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Australian Flu and the dilemma of naming diseases
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
Oncology drugs under AMNOG
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... against ‘treatment of physician’s
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
-
Senior Medical Writer
-
Competitive salary and benefits
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
-
Director – Healthcare PR
-
Salary TBC
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Novasecta
We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
